Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Eylea Bio-AG Snags 60% Share in Just 3 Months, Outpacing Biosimilar
The biologic authorized generic (bio-AG) version of Bayer's age-related macular degeneration drug Eylea (aflibercept) captured some 60% of the aflibercept 40 mg/mL market by volume within three months of launch, roughly tripling the biosimilar’s share, Jiho has learned. According to…
To read the full story
Related Article
- Eylea Biosimilar Shipment Restrictions to Be Lifted on June 5
May 27, 2026
- Santen’s Eylea Sales Fall 15.9% amid Re-Pricing, Biosimilar Entry
May 13, 2026
- Fuji’s Eylea Biosimilar Logs 776 Million Yen in First 3 Months
May 13, 2026
- Eylea Biosimilar Supply Curbed amid Originator Disruption
April 14, 2026
- Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
BUSINESS
- Lenvima-Welireg Combo Gets US Nod for Advanced RCC
September 28, 2026
- Daiichi Sankyo Pulls US Filing for B7-H3 ADC in SCLC
September 28, 2026
- Narcolepsy Diagnosis Still Takes Nearly 9 Years in Japan: Expert
September 28, 2026
- Japan OTC Market Down for 6th Straight Month in August: Intage
September 28, 2026
- IHH Unit Appeals Dismissal of 203 Billion Yen Daiichi Sankyo Suit
September 28, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…